These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 28900067)

  • 1. [Dimethyl Fumarate in Multiple Sclerosis].
    Tanaka M; Shimizu Y
    Brain Nerve; 2017 Sep; 69(9):1041-1046. PubMed ID: 28900067
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and Safety of Delayed-release Dimethyl Fumarate for Relapsing-remitting Multiple Sclerosis in Prior Interferon Users: An Integrated Analysis of DEFINE and CONFIRM.
    Fernández Ó; Giovannoni G; Fox RJ; Gold R; Phillips JT; Potts J; Okwuokenye M; Marantz JL
    Clin Ther; 2017 Aug; 39(8):1671-1679. PubMed ID: 28751099
    [TBL] [Abstract][Full Text] [Related]  

  • 3. 72-Week Safety and Tolerability of Dimethyl Fumarate in Japanese Patients with Relapsing-remitting Multiple Sclerosis: Analysis of the Randomised, Double Blind, Placebo-Controlled, Phase III APEX Study and its Open-Label Extension.
    Ochi H; Niino M; Onizuka Y; Hiramatsu K; Hase M; Yun J; Matta A; Torii S
    Adv Ther; 2018 Oct; 35(10):1598-1611. PubMed ID: 30206820
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-term safety and efficacy of dimethyl fumarate for up to 13 years in patients with relapsing-remitting multiple sclerosis: Final ENDORSE study results.
    Gold R; Arnold DL; Bar-Or A; Fox RJ; Kappos L; Mokliatchouk O; Jiang X; Lyons J; Kapadia S; Miller C
    Mult Scler; 2022 Apr; 28(5):801-816. PubMed ID: 34465252
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-term effects of delayed-release dimethyl fumarate in multiple sclerosis: Interim analysis of ENDORSE, a randomized extension study.
    Gold R; Arnold DL; Bar-Or A; Hutchinson M; Kappos L; Havrdova E; MacManus DG; Yousry TA; Pozzilli C; Selmaj K; Sweetser MT; Zhang R; Yang M; Potts J; Novas M; Miller DH; Kurukulasuriya NC; Fox RJ; Phillips TJ
    Mult Scler; 2017 Feb; 23(2):253-265. PubMed ID: 27207449
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Diroximel Fumarate Demonstrates an Improved Gastrointestinal Tolerability Profile Compared with Dimethyl Fumarate in Patients with Relapsing-Remitting Multiple Sclerosis: Results from the Randomized, Double-Blind, Phase III EVOLVE-MS-2 Study.
    Naismith RT; Wundes A; Ziemssen T; Jasinska E; Freedman MS; Lembo AJ; Selmaj K; Bidollari I; Chen H; Hanna J; Leigh-Pemberton R; Lopez-Bresnahan M; Lyons J; Miller C; Rezendes D; Wolinsky JS;
    CNS Drugs; 2020 Feb; 34(2):185-196. PubMed ID: 31953790
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dimethyl fumarate: a possible exit strategy from natalizumab treatment in patients with multiple sclerosis at risk for severe adverse events.
    Calabrese M; Pitteri M; Farina G; Bajrami A; Castellaro M; Magliozzi R; Monaco S
    J Neurol Neurosurg Psychiatry; 2017 Dec; 88(12):1073-1078. PubMed ID: 28844068
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Simple parameters from complete blood count predict lymphopenia, adverse effects and efficacy in people with MS treated with dimethyl fumarate.
    Baeva ME; Metz LM; Greenfield J; Camara-Lemarroy CR
    Mult Scler Relat Disord; 2023 Jun; 74():104699. PubMed ID: 37031552
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Progressive multifocal leukoencephalopathy in dimethyl fumarate-treated multiple sclerosis patients.
    Jordan AL; Yang J; Fisher CJ; Racke MK; Mao-Draayer Y
    Mult Scler; 2022 Jan; 28(1):7-15. PubMed ID: 32808554
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dimethyl fumarate selectively reduces memory T cells in multiple sclerosis patients.
    Longbrake EE; Ramsbottom MJ; Cantoni C; Ghezzi L; Cross AH; Piccio L
    Mult Scler; 2016 Jul; 22(8):1061-1070. PubMed ID: 26459150
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment response to dimethyl fumarate is characterized by disproportionate CD8+ T cell reduction in MS.
    Fleischer V; Friedrich M; Rezk A; Bühler U; Witsch E; Uphaus T; Bittner S; Groppa S; Tackenberg B; Bar-Or A; Zipp F; Luessi F
    Mult Scler; 2018 Apr; 24(5):632-641. PubMed ID: 28436295
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lower lymphocyte counts and older age are associated with reduced multiple sclerosis disease activity during dimethyl fumarate treatment.
    Garbo R; Lorenzut S; Del Negro I; Merlino G; Gigli GL; Cargnelutti D; Valente M
    Mult Scler Relat Disord; 2021 Apr; 49():102781. PubMed ID: 33524927
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of Aspirin Pretreatment or Slow Dose Titration on Flushing and Gastrointestinal Events in Healthy Volunteers Receiving Delayed-release Dimethyl Fumarate.
    O'Gorman J; Russell HK; Li J; Phillips G; Kurukulasuriya NC; Viglietta V
    Clin Ther; 2015 Jul; 37(7):1402-1419.e5. PubMed ID: 25999183
    [TBL] [Abstract][Full Text] [Related]  

  • 14. An evaluation of dimethyl fumarate for the treatment of relapsing remitting multiple sclerosis.
    Valencia-Sanchez C; Carter JL
    Expert Opin Pharmacother; 2020 Aug; 21(12):1399-1405. PubMed ID: 32543241
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of dimethyl fumarate on lymphocytes in RRMS: Implications for clinical practice.
    Mehta D; Miller C; Arnold DL; Bame E; Bar-Or A; Gold R; Hanna J; Kappos L; Liu S; Matta A; Phillips JT; Robertson D; von Hehn CA; Campbell J; Spach K; Yang L; Fox RJ
    Neurology; 2019 Apr; 92(15):e1724-e1738. PubMed ID: 30918100
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Relapses Requiring Intravenous Steroid Use and Multiple-Sclerosis-related Hospitalizations: Integrated Analysis of the Delayed-release Dimethyl Fumarate Phase III Studies.
    Giovannoni G; Gold R; Fox RJ; Kappos L; Kita M; Yang M; Sarda SP; Zhang R; Viglietta V; Havrdova E
    Clin Ther; 2015 Nov; 37(11):2543-51. PubMed ID: 26526385
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Real-life persistence and tolerability with dimethyl fumarate.
    Sejbaek T; Nybo M; Petersen T; Illes Z
    Mult Scler Relat Disord; 2018 Aug; 24():42-46. PubMed ID: 29906666
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Design of oral agents for the management of multiple sclerosis: benefit and risk assessment for dimethyl fumarate.
    Nicholas JA; Boster AL; Imitola J; O'Connell C; Racke MK
    Drug Des Devel Ther; 2014; 8():897-908. PubMed ID: 25045248
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safety and efficacy of dimethyl fumarate in multiple sclerosis: a multi-center observational study.
    Miclea A; Leussink VI; Hartung HP; Gold R; Hoepner R
    J Neurol; 2016 Aug; 263(8):1626-32. PubMed ID: 27260297
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical outcomes in patients with relapsing-remitting multiple sclerosis who switch from natalizumab to delayed-release dimethyl fumarate: A multicenter retrospective observational study (STRATEGY).
    Cohan SL; Moses H; Calkwood J; Tornatore C; LaGanke C; Smoot KE; Meka V; Okwuokenye M; Hotermans C; Mendoza JP; Mann MK; Meltzer LA
    Mult Scler Relat Disord; 2018 May; 22():27-34. PubMed ID: 29524759
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.